News & Updates

Treatment with dupilumab significantly improved lung function in children with moderate-to-severe type 2 asthma compared with placebo, according to two post hoc analyses presented at ERS 2023.

An analysis using data from the Barwon Infant Study (BIS) revealed that a more mature infant gut microbiota in late infancy may protect against the development of atopic wheeze in early childhood.

Alirocumab administered every 2 or 4 weeks (Q2W or Q4W) significantly reduced low-density lipoprotein-cholesterol (LDL-C) levels in paediatric patients with heterozygous familial hypercholesterolaemia (HeFH), according to a study presented at ESC 2023.

Treatment with deferasirox twice daily, compared with a once-daily regimen, results in significant improvements in the iron chelation efficacy and tolerability among transfusion-dependent paediatric beta-thalassaemia patients, a study has shown.

New drug applications approved by US FDA as of 01-15 September 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.